Imaging serotonin transporters using [123I]ADAM SPECT in a parkinsonian primate model

Applied Radiation and Isotopes

Volumn 66, Issue 12, 2008, Pages 1799-1803

  Ma, Kuo Hsing ^a   Huang, Wen Sheng ^b   Huang, San Yuan ^b   Cheng, Cheng Yi ^b   Chen, Ching Yuan ^c   Shen, Lie Hang ^d   Liu, Jiang Chuan ^a   Fu, Ying Kai ^d,e  

^a NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^b TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^c BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

^d INSTITUTE OF NUCLEAR ENERGY RESEARCH   (Taiwan)

^e CHUNG YUAN CHRISTIAN UNIVERSITY   (Taiwan)

Author keywords

123I ADAM; 99mTc TRODAT 1; Parkinson's disease; SPECT

Indexed keywords

[123I]ADAM; [99MTC] TRODAT-1; PARKINSON'S DISEASE; SPECT;

2 [[2 [(DIMETHYLAMINO)METHYL]PHENYL]THIO] 5 IODOPHENYLAMINE I 123; [2 [[2 [[[3 (4 CHLOROPHENYL) 8 METHYL 8 AZABICYCLO[3.2.1]OCT 2 YL]METHYL](2 MERCAPTOETHYL)AMINO]ETHYL]AMINO]ETHANETHIOLATO]OXOTECHNETIUM TC 99M; RADIOLIGAND; RADIOPHARMACEUTICAL AGENT; SEROTONIN TRANSPORTER; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COLLIMATOR; CONTROLLED STUDY; CORPUS STRIATUM; DRUG UPTAKE; FRONTAL CORTEX; MEDIAL FOREBRAIN BUNDLE; MESENCEPHALON; MONKEY; NEUROIMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSONISM; PRIMATE; PRIORITY JOURNAL; SCINTILLATION CAMERA; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; THALAMUS;

ANIMALS; BRAIN; CINANSERIN; DISEASE MODELS, ANIMAL; MACACA; PARKINSONIAN DISORDERS; RADIOPHARMACEUTICALS; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 53749095034     PISSN: 09698043     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.apradiso.2008.06.033     Document Type: Article

References (34)

1. 2 in chromaffin cells. Eur. J. Pharmacol. 293 (1995) 55-64
2. Annett L.E., Rogers D.C., Hernandez T.D., and Dunnett S.B. Behavioural analysis of unilateral monoamine depletion in the marmoset. Brain 115 Part 3 (1992) 825-856
3. Bernheimer H., Birkmayer W., and Hornykiewicz O. Distribution of 5-hydroxytryptamine serotonin in the human brain and its behavior in patients with Parkinson's syndrome. Klin Wochenschr 39 (1961) 1056-1059
4. Blum D., Torch S., Nissou M.F., Benabid A.L., and Verna J.M. Extracellular toxicity of 6-ydroxydopamine on PC12 cells. Neurosci. Lett. 283 (2000) 193-196
5. Blum D., Torch S., Lambeng N., et al. Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease. Prog. Neurobiol. 65 (2001) 135-172
6. Breese G.R., and Traylor T.D. Effect of 6-hydroxydopamine on brain norepinephrine and dopamine evidence for selective degeneration of catecholamine neurons. J. Pharmacol. Exp. Ther. 174 (1970) 413-420
7. Chinaglia G., Landwehrmeyer B., Probst A., and Palacios J.M. Serotoninergic terminal transporters are differentially affected in Parkinson's disease and progressive supranuclear palsy: an autoradiographic study with [3H]citalopram. Neuroscience 54 (1993) 691-699
8. D'Amato R.J., Zweig R.M., Whitehouse P.J., et al. Aminergic systems in Alzheimer's disease and Parkinson's disease. Ann. Neurol. 22 (1987) 229-236
9. Decker D.E., Althaus J.S., Buxser S.E., VonVoigtlander P.F., and Ruppel P.L. Competitive irreversible inhibition of dopamine uptake by 6-hydroxydopamine. Res. Commun. Chem. Pathol. Pharmacol. 79 (1993) 195-208
10. Dodel R.C., Du Y., Bales K.R., Ling Z., Carvey P.M., and Paul S.M. Caspase-3-like proteases and 6-hydroxydopamine induced neuronal cell death. Brain Res. Mol. Brain Res. 64 (1999) 141-148
11. Fahn S., Libsch L.R., and Cutler R.W. Monoamines in the human neostriatum: topographic distribution in normals and in Parkinson's disease and their role in akinesia, rigidity, chorea, and tremor. J. Neurol. Sci. 14 (1971) 427-455
12. Gordon B.G., DeBoer J.M., Wooldridge L.D., and Sharp J.G. Effect of 6-hydroxydopamine on murine hematopoietic stem cells: enhanced cytotoxicity on megakaryocyte colony forming units. Life Sci. 49 (1991) 121-127
13. Guttman M., Boileau I., Warsh J., et al. Brain serotonin transporter binding in non-depressed patients with Parkinson's disease. Eur. J. Neurol. 14 (2007) 523-528
14. Halliday G.M., Blumbergs P.C., Cotton R.G., Blessing W.W., and Geffen L.B. Loss of brainstem serotonin- and substance P-containing neurons in Parkinson's disease. Brain Res. 510 (1990) 104-107
15. Halliday G.M., Li Y.W., Blumbergs P.C., et al. Neuropathology of immunohistochemically identified brainstem neurons in Parkinson's disease. Ann. Neurol. 27 (1990) 373-385
16. Huang W.S., Ma K.H., Chou Y.H., Chen C.Y., Liu R.S., and Liu J.C. 99mTc-TRODAT-1 SPECT in healthy and 6-OHDA lesioned parkinsonian monkeys: comparison with 18F-FDOPA PET. Nucl. Med. Commun. 24 (2003) 77-83
17. Huang W.S., Ma K.H., Cheng C.Y., et al. Imaging serotonin transporters with 123I-ADAM brain SPECT in healthy non-human primates. Nucl. Med. Commun. 25 (2004) 515-519
18. Jellinger K. Overview of morphological changes in Parkinson's disease. Adv. Neurol. 45 (1987) 1-18
19. Kish S.J. Biochemistry of Parkinson's disease: is a brain serotonergic deficiency a characteristic of idiopathic Parkinson's disease. Adv. Neurol. 91 (2003) 39-49
20. Laruelle M., Baldwin R.M., Malison R.T., et al. SPECT imaging of dopamine and serotonin transporters with [123I]beta-CIT: pharmacological characterization of brain uptake in nonhuman primates. Synapse 13 (1993) 295-309
21. Lotharius J., Dugan L.L., and O'Malley K.L. Distinct mechanisms underlie neurotoxin-mediated cell death in cultured dopaminergic neurons. J. Neurosci. 19 (1999) 1284-1293
22. Ma K.H., Huang W.S., Chen C.H., et al. Dual SPECT of dopamine system using [99mTc]TRODAT-1 and [123I]IBZM in normal and 6-OHDA-lesioned formosan rock monkeys. Nucl. Med. Biol. 29 (2002) 561-567
23. Martinez D., Broft A., and Laruelle M. Imaging neurochemical endophenotypes: promises and pitfalls. Pharmacogenomics 2 (2001) 223-237
24. Mayeux R. Depression in the patient with Parkinson's disease. J. Clin. Psychiatry 51 Suppl 20-23 (1990) (discussion 24-25)
25. Newman-Tancredi A., Cussac D., Quentric Y., et al. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor III agonist and antagonist properties at serotonin, 5-HT(1) and 5-HT(2), receptor subtypes. J. Pharmacol. Exp. Ther. 303 (2002) 815-822
26. Oya S., Choi S.R., Hou C., et al. 2-((2-((dimethylamino)methyl)phenyl)thio)-5-iodophenylamine (ADAM): an improved serotonin transporter ligand. Nucl. Med. Biol. 27 (2000) 249-254
27. Paulus W., and Jellinger K. The neuropathologic basis of different clinical subgroups of Parkinson's disease. J. Neuropathol. Exp. Neurol. 50 (1991) 743-755
28. Raisman R., Cash R., and Agid Y. Parkinson's disease: decreased density of 3H-imipramine and 3H-paroxetine binding sites in putamen. Neurology 36 (1986) 556-560
29. Rinne U.K., Sonninen V., Riekkinen P., and Laaksonen H. Dopaminergic nervous transmission in Parkinson's disease. Med. Biol. 52 (1974) 208-217
30. Scatton B., Javoy-Agid F., Rouquier L., Dubois B., and Agid Y. Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson's disease. Brain Res. 275 (1983) 321-328
31. Seitz G., Stegmann H.B., Jager H.H., et al. Neuroblastoma cells expressing the noradrenaline transporter are destroyed more selectively by 6-fluorodopamine than by 6-hydroxydopamine. J. Neurochem. 75 (2000) 511-520
32. Storch A., Kaftan A., Burkhardt K., and Schwarz J. 6-Hydroxydopamine toxicity towards human SH-SY5Y dopaminergic neuroblastoma cells: independent of mitochondrial energy metabolism. J. Neural Transm. 107 (2000) 281-293
33. Wilson J.M., Levey A.I., Rajput A., et al. Differential changes in neurochemical markers of striatal dopamine nerve terminals in idiopathic Parkinson's disease. Neurology 47 (1996) 718-726
34. Yamada K., Umegaki H., Maezawa I., Iguchi A., Kameyama T., and Nabeshima T. Possible involvement of catalase in the protective effect of interleukin-6 against 6-hydroxydopamine toxicity in PC12 cells. Brain Res. Bull. 43 (1997) 573-574